8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Apr 9, 2026·SEC
Theriva Biologics, Inc.(TOVX)Earnings, Financials & Key Ratios
TOVX•AMEX
Price updated Jun 19, 2026
AboutTheriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.Show more
- Revenue$0
- EBITDA-$15M+43.1%
- Net Income-$25M+1.6%
- EPS (Diluted)-2.08+89.1%
- ROE-146.58%-67.9%
TOVX Key Insights
Theriva Biologics, Inc. (TOVX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 20.2% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TOVX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TOVX Price & Volume
Theriva Biologics, Inc. (TOVX) stock price & volume — 10-year historical chart
Loading chart...
TOVX Growth Metrics
Theriva Biologics, Inc. (TOVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.77%
Return on Capital
10 Years-141%
5 Years-46.58%
3 Years-53.53%
Last Year-53.65%
TOVX Recent Earnings
Theriva Biologics, Inc. (TOVX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.05+0.0%
$0.05
Rev
$300,000
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$1.85+525.3%
$0.43
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.45-18.4%
$0.38
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$1.93-407.9%
$0.38
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.05vs $0.05+0.0% | $300,000 |
| Q2 2026 | Mar 12, 2026 | $1.85vs $0.43+525.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.45vs $0.38-18.4% | — |
| Q3 2025 | Aug 11, 2025 | $1.93vs $0.38-407.9% | — |
Based on last 12 quarters of dataView full earnings history →
TOVX Peer Comparison
Theriva Biologics, Inc. (TOVX) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 CRVS | 1B | 11.91 | -22.47 | -38.92% | 0.02 | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMMP | 55.08M | 0.37 | -1.27 | 31.28% | -11.72% | -72.51% | 0.01 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 VVOS | 2.94M | 0.50 | -0.24 | 16.05% | -128.36% | -23.38% | ||
 SNDX | 1.68B | 19.00 | -5.78 | 6.28% | -112.01% | -256.66% | 5.36 |
Compare TOVX vs Peers
Theriva Biologics, Inc. (TOVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TOVX Income Statement
Theriva Biologics, Inc. (TOVX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 300K |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 245K | 272K | 0 | 0 | 0 | 0 | 0 | 0 | 108K | 24K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -245K▲ 0% | -272K▼ 11.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -108K▲ 0% | 276K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | 92% |
Gross Profit Growth % | -56.05% | -11.02% | 100% | - | - | - | - | - | - | - |
Operating Expenses | 26.25M | 17.57M | 15.66M | 10.16M | 14.27M | 21.58M | 21.43M | 26.35M | 14.91M | 22.01M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 7.47M | 5.73M | 4.58M | 5.03M | 6.47M | 7.57M | 7.78M | 7.4M | 15.45M | 16.07M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 18.78M | 11.84M | 11.08M | 5.13M | 7.8M | 11.72M | 14.31M | 12.03M | 8.6M | 5.99M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 2.29M | -660K | 6.92M | -9.14M | -51K |
Operating Income | -26.25M▲ 0% | -17.57M▲ 33.1% | -15.66M▲ 10.9% | -10.16M▲ 35.1% | -14.27M▼ 40.5% | -21.58M▼ 51.2% | -21.43M▲ 0.7% | -26.35M▼ 22.9% | -15.02M▲ 43.0% | -21.73M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | -7245% |
Operating Income Growth % | 33.12% | 33.07% | 10.86% | 35.13% | -40.49% | -51.19% | 0.7% | -22.93% | 42.99% | - |
EBITDA | -26.01M | -17.3M | -15.42M | -9.96M | -14.19M | -21.5M | -21.3M | -26.21M | -14.91M | -21.63M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | -7209.67% |
EBITDA Growth % | 33.48% | 33.48% | 10.84% | 35.43% | -42.45% | -51.52% | 0.93% | -23.07% | 43.1% | 13.7% |
D&A (Non-Cash Add-back) | 245K | 272K | 240K | 201K | 87K | 85K | 135K | 137K | 108K | 106K |
EBIT | -26.25M | -17.57M | -15.66M | -10.16M | -14.27M | -19.29M | -22.09M | -19.43M | -15.02M | -21.66M |
Net Interest Income | 0 | 0 | 283K | 44K | 6K | 512K | 1.44M | 697K | 287K | 273K |
Interest Income | 21K | 67K | 283K | 44K | 6K | 512K | 1.44M | 697K | 287K | 273K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 10.76M | 4.15M | 283K | 44K | 6K | 471K | 1.44M | 693K | -8.72M | 276K |
Pretax Income | -15.49M▲ 0% | -13.42M▲ 13.4% | -15.38M▼ 14.6% | -10.12M▲ 34.2% | -14.27M▼ 41.0% | -21.11M▼ 48.0% | -19.99M▲ 5.3% | -25.65M▼ 28.3% | -23.74M▲ 7.5% | -21.46M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | -7153% |
Income Tax | 0 | 0 | 0 | 0 | 0 | -1.43M | -1.64M | 0 | 1.51M | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 6.75% | 8.2% | 0% | -6.36% | 0% |
Net Income | -15.17M▲ 0% | -13.37M▲ 11.9% | -15.3M▼ 14.5% | -10.04M▲ 34.4% | -14.27M▼ 42.1% | -19.68M▼ 38.0% | -18.35M▲ 6.8% | -25.65M▼ 39.8% | -25.25M▲ 1.6% | -21.46M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | -7153% |
Net Income Growth % | 44.33% | 11.91% | -14.48% | 34.37% | -42.06% | -37.98% | 6.79% | -39.81% | 1.57% | 13.52% |
Net Income (Continuing) | -15.49M | -13.42M | -15.38M | -10.12M | -14.27M | -19.68M | -18.35M | -25.65M | -25.25M | -21.46M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -1.91M | -2.91M | -2.88M | -2.77M | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -42.70▲ 0% | -21.45▲ 49.8% | -9.14▲ 57.4% | -6.60▲ 27.8% | -1.90▲ 71.2% | -32.66▼ 1618.9% | -28.48▲ 12.8% | -19.03▲ 33.2% | -2.08▲ 89.1% | -0.52▲ 0% |
EPS Growth % | 57.79% | 49.77% | 57.39% | 27.79% | 71.21% | -1618.95% | 12.8% | 33.18% | 89.07% | 87.77% |
EPS (Basic) | -42.70 | -21.45 | -9.14 | -6.60 | -1.90 | -32.66 | -28.49 | -19.03 | -2.08 | - |
Diluted Shares Outstanding | 355.33K | 623.24K | 1.64M | 1.9M | 12.19M | 613.09K | 644.28K | 1.35M | 12.14M | 41.07M |
Basic Shares Outstanding | 355.33K | 623.24K | 1.64M | 1.9M | 12.19M | 613.09K | 644K | 1.35M | 12.14M | 41.07M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TOVX Balance Sheet
Theriva Biologics, Inc. (TOVX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 17.94M | 29.51M | 16.43M | 7.93M | 68.86M | 45.52M | 27.4M | 16.28M | 17.47M | 16.76M |
Cash & Short-Term Investments | 17.12M | 28.92M | 15.04M | 6.23M | 67.33M | 41.79M | 23.18M | 11.61M | 13.06M | 14.43M |
Cash Only | 17.12M | 28.92M | 15.04M | 6.23M | 67.33M | 41.79M | 23.18M | 11.61M | 13.06M | 14.43M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 46K | 0 | 3K | 469K | 0 | 231K | 1.94M | 3.32M | 3.83M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 2.29K |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 458K | 0 | 0 | 0 | 576K | 2.33M |
Total Non-Current Assets | 895K | 630K | 809K | 476K | 1.51M | 26.34M | 27.82M | 19.07M | 20.77M | 21.49M |
Property, Plant & Equipment | 872K | 607K | 786K | 453K | 1.48M | 1.54M | 2.18M | 1.54M | 1.02M | 2.14M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.21x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 5.53M | 5.7M | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 19.15M | 19.75M | 17.36M | 19.62M | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 99K | 102K | 0 | 46K | 92K |
Other Non-Current Assets | 23K | 23K | 23K | 23K | 23K | -3.15M | 78K | 171K | 82K | 19.35M |
Total Assets | 18.84M▲ 0% | 30.14M▲ 60.0% | 17.23M▼ 42.8% | 8.41M▼ 51.2% | 70.36M▲ 736.7% | 71.86M▲ 2.1% | 55.22M▼ 23.2% | 35.35M▼ 36.0% | 38.24M▲ 8.2% | 38.25M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.01x |
Asset Growth % | -16.27% | 60% | -42.82% | -51.2% | 736.68% | 2.13% | -23.16% | -35.98% | 8.17% | -11.5% |
Total Current Liabilities | 9.79M | 3.38M | 5.28M | 2.97M | 3.55M | 7.06M | 6.74M | 7.58M | 10.01M | 10.26M |
Accounts Payable | 2.02M | 1.03M | 2.31M | 886K | 524K | 915K | 770K | 859K | 1.01M | 608K |
Days Payables Outstanding | 3.01K | 1.39K | - | - | - | - | - | - | 3.43K | 11.5K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 57K | 63K | 61K | 606K | 545K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4.17M | 99K | 0 | 868K | 0 | 4.47M | 906K | 1.8M | 8.39M | 9.11M |
Current Ratio | 1.83x | 8.72x | 3.11x | 2.67x | 19.37x | 6.45x | 4.07x | 2.15x | 1.74x | 1.63x |
Quick Ratio | 1.83x | 8.72x | 3.11x | 2.67x | 19.37x | 6.45x | 4.07x | 2.15x | 1.74x | 1.63x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -9.2K |
Total Non-Current Liabilities | 12.46M | 302K | 473K | 186K | 1.4M | 10.24M | 8.78M | 8.7M | 12.84M | 12.59M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 221K | 162K | 92K | 1.67M | 1.52M |
Capital Lease Obligations | 0 | 0 | 473K | 186K | 1.4M | 1.19M | 1.44M | 873K | 352K | 1.37M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 1.62M | 0 | 762K | 0 | 430K |
Other Non-Current Liabilities | 402K | 302K | 0 | 0 | 0 | 7.21M | 7.18M | 6.97M | 10.82M | 11.06M |
Total Liabilities | 22.25M | 3.69M | 5.75M | 3.15M | 4.96M | 17.3M | 15.52M | 16.29M | 22.86M | 22.85M |
Total Debt | 0 | 0 | 722K | 473K | 1.53M | 1.68M | 2.15M | 1.56M | 2.63M | 2.07M |
Net Debt | -17.12M | -28.92M | -14.32M | -5.75M | -65.8M | -40.1M | -21.02M | -10.04M | -10.43M | -12.36M |
Debt / Equity | - | - | 0.06x | 0.09x | 0.02x | 0.03x | 0.05x | 0.08x | 0.17x | 0.13x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.10x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.57x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | -3.41M▲ 0% | 26.45M▲ 875.8% | 11.49M▼ 56.6% | 5.26M▼ 54.2% | 65.41M▲ 1144.0% | 54.56M▼ 16.6% | 39.7M▼ 27.2% | 19.07M▼ 52.0% | 15.38M▼ 19.3% | 15.4M▲ 0% |
Equity Growth % | -251.62% | 875.81% | -56.58% | -54.23% | 1143.97% | -16.58% | -27.25% | -51.97% | -19.32% | -154.18% |
Book Value per Share | -9.60 | 42.45 | 6.99 | 2.77 | 5.37 | 89.00 | 61.61 | 14.14 | 1.27 | 0.37 |
Total Shareholders' Equity | -1.5M | 29.36M | 14.37M | 8.03M | 65.41M | 54.56M | 39.7M | 19.07M | 15.38M | 15.4M |
Common Stock | 129K | 15K | 17K | 29K | 13K | 16K | 18K | 3K | 34K | 45K |
Retained Earnings | -194.17M | -219.46M | -235.54M | -248.09M | -271.28M | -290.97M | -309.32M | -334.97M | -358.71M | -360.75M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -288K | -288K | -288K | -288K | 0 |
Accumulated OCI | -12.05M | 0 | 0 | 0 | 0 | -679K | 32K | -1.18M | 755K | 377K |
Minority Interest | -1.91M | -2.91M | -2.88M | -2.77M | 0 | 0 | 0 | 0 | 0 | 0 |
TOVX Cash Flow Statement
Theriva Biologics, Inc. (TOVX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.2M | -17.28M | -13.87M | -12.17M | -12.89M | -19.08M | -19M | -16.94M | -16.67M | -14.37M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 27.59% | 14.48% | 19.71% | 12.29% | -5.93% | -48.04% | 0.45% | 10.84% | 1.58% | 40.05% |
Net Income | -15.49M | -13.42M | -15.38M | -10.12M | -14.27M | -19.68M | -18.35M | -25.65M | -23.74M | -21.46M |
Depreciation & Amortization | 245K | 272K | 240K | 201K | 87K | 85K | 135K | 137K | 108K | 106K |
Stock-Based Compensation | 3.41M | 2.07M | 340K | 350K | 416K | 475K | 552K | 671K | 654K | 288K |
Deferred Taxes | 0 | -4.08M | 0 | 0 | 0 | -1.43M | -1.64M | -888K | 0 | -409K |
Other Non-Cash Items | -10.74M | 71K | 72K | 178K | 166K | 2.27M | -2M | 8.07M | 9.37M | 10.2M |
Working Capital Changes | 2.37M | -2.19M | 855K | -2.78M | 709K | -806K | 2.31M | 726K | -3.06M | -3.09M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 27K | -987K | 1.28M | -1.43M | -363K | -385K | -157K | 123K | 69K | 112K |
Cash from Investing | -212K | -7K | 0 | -9K | -14K | -4.4M | -202K | -1K | -35K | -35K |
Capital Expenditures | -212K | -7K | 0 | -9K | -14K | -116K | -202K | -1K | -35K | -35K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 11.67% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -4.28M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -4.28K | 0 | 0 | 0 | 0 |
Cash from Financing | 18.48M | 29.09M | 0 | 3.36M | 74M | -1.93M | 625K | 5.5M | 18.19M | 18.99M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -1.38M | -75K | -67K | 1.44M | 43K |
Equity Issued (Net) | 18.31M | 29.09M | 0 | 3.36M | 65.96M | 2.45M | 2.22M | 5.56M | 13.53M | 15.83M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -288K | 0 | 0 | 0 | 0 |
Other Financing | 166K | 0 | 0 | 0 | 8.04M | -3M | -1.52M | 0 | 3.23M | 3.11M |
Net Change in Cash | -1.94M▲ 0% | 11.8M▲ 708.7% | -13.87M▼ 217.5% | -8.82M▲ 36.4% | 61.1M▲ 792.9% | -25.44M▼ 141.6% | -18.61M▲ 26.9% | -11.57M▲ 37.8% | 1.4M▲ 112.1% | 4.42M▲ 0% |
Free Cash Flow | -20.42M▲ 0% | -17.29M▲ 15.3% | -13.87M▲ 19.7% | -12.18M▲ 12.2% | -12.9M▼ 6.0% | -19.2M▼ 48.8% | -19.2M▲ 0.0% | -16.94M▲ 11.8% | -16.7M▲ 1.4% | -14.4M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | -4801.33% |
FCF Growth % | 28.29% | 15.33% | 19.74% | 12.23% | -5.97% | -48.78% | 0% | 11.77% | 1.38% | 14.33% |
FCF per Share | -57.46 | -27.74 | -8.44 | -6.41 | -1.06 | -31.31 | -29.80 | -12.56 | -1.38 | -0.35 |
FCF Conversion (FCF/Net Income) | 1.33x | 1.29x | 0.91x | 1.21x | 0.90x | 0.97x | 1.04x | 0.66x | 0.66x | 0.67x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TOVX Key Ratios
Theriva Biologics, Inc. (TOVX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -116.01% | -80.67% | -119.95% | -40.38% | -32.82% | -38.93% | -87.31% | -146.58% | -178.29% |
Return on Invested Capital (ROIC) | - | - | - | - | - | -230.09% | -97.02% | -142.68% | -161.17% | -574.14% |
Gross Margin | - | - | - | - | - | - | - | - | - | 92% |
Net Margin | - | - | - | - | - | - | - | - | - | -7153% |
Debt / Equity | - | - | 0.06x | 0.09x | 0.02x | 0.03x | 0.05x | 0.08x | 0.17x | 0.13x |
FCF Conversion | 1.33x | 1.29x | 0.91x | 1.21x | 0.90x | 0.97x | 1.04x | 0.66x | 0.66x | 0.67x |
Related:TOVX Dividend History·TOVX Revenue History·TOVX Price History·TOVX P/E History·TOVX Financial Ratios·TOVX Institutional Holders
TOVX SEC Filings & Documents
Theriva Biologics, Inc. (TOVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TOVX Frequently Asked Questions
Theriva Biologics, Inc. (TOVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Theriva Biologics, Inc. (TOVX) reported $0.3M in revenue for fiscal year 2025. This represents a 200% increase from $0.1M in 1994.
Theriva Biologics, Inc. (TOVX) grew revenue by 0.0% over the past year. Growth has been modest.
Theriva Biologics, Inc. (TOVX) reported a net loss of $21.5M for fiscal year 2025.
Dividend & Returns
Theriva Biologics, Inc. (TOVX) has a return on equity (ROE) of -146.6%. Negative ROE indicates the company is unprofitable.
Theriva Biologics, Inc. (TOVX) had negative free cash flow of $14.4M in fiscal year 2025, likely due to heavy capital investments.